The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, is the lead asset. It is a second-gen CD40 inhibitor. There were a number of first-gen anti-CD40 antibodies in ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

Novartis stops liver transplant program after Astellas drug beats its CD40 prospect in phase 2 Despite ... the list of targeted indications for its CD40L monoclonal antibody frexalimab after ...

The work focuses on the interaction of B cells and T cells in the body's immune system via two proteins—CD40 on B cells and CD40L on T cells—in an immune deficiency disease called X-linked ...